Parkinson's Disease/Movement Disorders News

Individuals who engaged in some form of exercise or physical activity on a regular or semi-regular basis demonstrated better brain health compared with inactive individuals, according to research from Nature Aging.

Deep brain stimulation (DBS) therapy has been a safe and effective treatment option for Parkinson’s disease for more than 30 years, but another surgical option for the therapy has emerged.

A Georgia-based biotechnology company has secured a U.S. patent for an exosome-based therapy to treat neuroinflammation that occurs in a range of neurodegenerative disease, according to the manufacturer.

In two large trials of individuals with Parkinson’s disease, dementia occurred less frequently and later in the disease course than previously thought, according to new research published in Neurology.

The first 100 patients have been enrolled in a clinical trial investigating a novel light therapy device intended to treat individuals with Parkinson’s disease, according to the manufacturer.

The FDA has approved Medtronic’s Asleep Deep Brain Stimulation surgery for individuals diagnosed with Parkinson’s disease as well as those with essential tremor, according to the manufacturer.

The FDA has approved Crexont extended-release capsules for the treatment of Parkinson’s disease, according to the manufacturer.

Body composition patterns associated with weight and fat distribution were strongly correlated with neurodegenerative disease and brain aging, mediated by cardiovascular disease, according to research published in Neurology.

Annovis Bio Inc. has secured a U.S. patent for methods of treating acute traumatic brain injuries with its lead drug candidate, an oral, small molecule neurotoxic protein inhibitor.